A number of other equities research analysts have also recently commented on the company. Zacks Investment Research cut GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research note on Monday, May 13th. They set an “overweight” rating and a $21.00 target price on the stock. TheStreet cut Twin Disc from a “b-” rating to a “c+” rating in a research note on Tuesday, June 11th. ValuEngine upgraded Zillow Group from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Piper Jaffray Companies boosted their price objective on Beigene to $180.00 and gave the company an “overweight” rating in a research note on Thursday, May 9th. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Tabula Rasa HealthCare currently has an average rating of “Buy” and a consensus price target of $82.12.
NASDAQ TRHC opened at $54.25 on Friday. The company has a market cap of $1.19 billion, a PE ratio of 271.25 and a beta of 1.62. Tabula Rasa HealthCare has a one year low of $40.86 and a one year high of $91.16. The company has a quick ratio of 1.73, a current ratio of 1.80 and a debt-to-equity ratio of 1.31. The business’s fifty day simple moving average is $48.02.
In related news, Director Gordon Tunstall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $51.52, for a total value of $51,520.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $50.68, for a total value of $405,440.00. The disclosure for this sale can be found here. Insiders sold a total of 50,270 shares of company stock worth $2,457,654 over the last 90 days. 11.80% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of the business. LPL Financial LLC boosted its position in Tabula Rasa HealthCare by 47.6% in the 4th quarter. LPL Financial LLC now owns 6,105 shares of the company’s stock valued at $389,000 after buying an additional 1,968 shares during the last quarter. BlackRock Inc. boosted its position in Tabula Rasa HealthCare by 1.6% in the 4th quarter. BlackRock Inc. now owns 2,600,884 shares of the company’s stock valued at $165,831,000 after buying an additional 40,174 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Tabula Rasa HealthCare by 8.6% in the 4th quarter. Bank of New York Mellon Corp now owns 280,883 shares of the company’s stock valued at $17,910,000 after buying an additional 22,270 shares during the last quarter. Texas Permanent School Fund boosted its position in Tabula Rasa HealthCare by 5.1% in the 4th quarter. Texas Permanent School Fund now owns 11,116 shares of the company’s stock valued at $709,000 after buying an additional 544 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in Tabula Rasa HealthCare by 97.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 10,421 shares of the company’s stock valued at $664,000 after buying an additional 5,151 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.